Navigation Links
Alzheimer's disease: The first prevention study of its kind
Date:9/21/2011

This press release is available in French.

Researchers at the Douglas Mental Health University Institute, in Montreal, Quebec, are about to launch the first epidemiological study on the prevention of Alzheimer's disease.

"As far as we know, this is the first study of its kind to be carried out anywhere in the world," states John Breitner, the study's lead investigator and Director of the new Centre for Studies on Prevention of Alzheimer's Disease (StoP-Alzheimer). Dr John Breitner and Dr Judes Poirier, the Centre's Associate Director, will be recruiting 250 healthy adults aged 60 or over, who have (or had) a parent, brother or sister with Alzheimer's disease, in order to learn which methods are most effective at preventing this neurodegenerative condition.

Using a combined diagnostic approach of brain imaging and cerebrospinal fluid analysis, the researchers will observe their subjects' biomarkers for a period of ten years to find out which preventative agents can stop the disease from developing, long before symptoms appear. The preventative agents involvedfive in allhave already shown promising results in previous studies. They are anti-inflammatory medications, insulin, physical activity, the Mediterranean diet, and drugs stimulating the production of a protein connected to the apoE gene.

The future of Alzheimer's research

For more than a decade, research into the treatment of Alzheimer's disease, whether pharmacological or other, has not produced the desired results. To date, only some symptoms relating to cognitive decline or memory loss can be treated. Observations by scientists suggest that the focus should shift to prevention and that money should be invested in major studies into this aspect of the disease. "Alzheimer's is a public health crisis that could take on catastrophic proportions in the coming years. It is imperative that we find the prevention strategies that are most likely to succeed," stresses Dr Poirier.

Centre for Studies on Prevention of Alzheimer's Disease

Supported financially by McGill University and the professorial chair funded by pharmaceutical giant Pfizer, the Centre for Studies on Prevention of Alzheimer's Disease, based at the Douglas Institute, is committed to finding ways to stop the disease's progress long before any symptoms are noticed. The Centre will be able to draw on the findings of more than twenty scientists already studying brain aging. This new study by Dr Breitner and Dr Poirier is the first in a series that will be developed at the Centre.

"What we will be doing is similar to the work done on preventing heart disease, that is, to intervene before the damage is done," explains Dr Poirier.

The impact of disease prevention

Preventing the disease from manifesting itself, even if only for a few years, would have a huge impact on future generations, on families, on society, and on the health care system as a whole.

  • Postponing the disease's symptoms for two years represents 30% fewer cases for the current generation.

  • Push the symptoms back by five years, and the number of cases is cut by half within one generation. It's a crisis situation. Every year, the costs attributable to Alzheimer's disease are estimated to be between $6 billion and $8 billion in Canada alone.

  • Half a million Canadians suffer from Alzheimer's or a related dementia71,000 of those are under 75 years of age (Alzheimer's Society of Montreal).

  • A person who has a parent with Alzheimer's is two to three times more likely to develop the disease.


'/>"/>

Contact: Marie france Coutu
marie-france.coutu@douglas.mcgill.ca
514-835-3236
Douglas Mental Health University Institute
Source:Eurekalert

Related medicine news :

1. Thyroid Disease: The Hidden Epidemic
2. Understanding causes of cancer and chronic disease: The Canadian Partnership for Tomorrow Project
3. Patients at high risk of recurrences of heart disease: Breakthrough in prevention
4. Crohn's & Colitis Foundation National Event Helping Women Manage Inflammatory Bowel Disease: Two Women Physician Experts and Researchers in IBD on Interactive Webcast/Teleconference
5. HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study
6. Chronic Lyme disease: How often is it diagnosed and treated?
7. Parkinsons disease: Excess of special protein identified as key to symptoms and possible new target for treatment with widely used anti-cancer drug imatinib
8. Air Pollution Ups Risk of Chronic Lung Disease: Study
9. Shorter Sleep in Men Ups Risk of Heart Disease: Study
10. Destined for disease: Breast cancer mutation regulates cell fate
11. DMP for coronary heart disease: Current guidelines indicate some need for revision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... in many scientific laboratories. The assembly protocols involve many repetitive steps and often ... for automation, which enables the high-throughput needed, and results in a lower error ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... easier access to the robotic-assisted total-hip and partial-knee replacement surgeries that are ... at Forbes Hospital and Jefferson Hospital recently started performing these surgeries using ...
(Date:3/29/2017)... VA (PRWEB) , ... March 29, 2017 , ... ... its seventh North American office location in Richmond, Virginia, located at the Riverfront Plaza, ... 11, attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond ...
(Date:3/28/2017)... ... ... Tuesday, March 28, 2017, is the annual American Diabetes Association Alert Day, ... find out if they are at risk for developing Type 2 diabetes. In recognition ... by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower Crown Lights ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors is ... his extensive knowledge of appraisals, property values, ad valorem taxation, and government policy ... industry for more than 40 years. , “Ruel is a great addition to ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
(Date:3/29/2017)... 29, 2017 Neurim Pharmaceuticals ("Neurim") ... obtain exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... treat sleep disorders in children with Autism Spectrum Disorders (ASD) and ... approved for children. The collaboration with Exeltis will help ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The global patient safety and risk management software market ... Patient safety has become a priority for almost ... significantly in the last decade and is currently on the verge ...
Breaking Medicine Technology: